Fusion protein for the prevention, treatment or amelioration of kidney diseases
US-2026049114-A1 · Feb 19, 2026 · US
This page is not indexed by search engines while we improve data quality.
Powers Janine patents
Powers Janine is listed as an inventor on 14 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Powers Janine |
| Total patents | 14 |
| First publication | May 25, 2017 |
| Latest publication | Feb 19, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US-2025223367-A1 · Jul 10, 2025 · US
Medical use of interferon-lambda for the treatment of fibrosis
US-11975046-B2 · May 7, 2024 · US
Medical use of interferon-lambda for the treatment of fibrosis
US-2024000893-A1 · Jan 4, 2024 · US
Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
US-2023192870-A1 · Jun 22, 2023 · US
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US-2023052212-A1 · Feb 16, 2023 · US
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US-11447553-B2 · Sep 20, 2022 · US
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
US-11421034-B2 · Aug 23, 2022 · US
Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer
US-2021009697-A1 · Jan 14, 2021 · US
NOPE for treatment of pathological muscle loss and weakness
US-10799559-B2 · Oct 13, 2020 · US
Recent patents
Latest publications not already listed above.
Medical use of interferon-lambda for the treatment of fibrosis
US-2019374610-A1 · Dec 12, 2019 · US
Nope for treatment of pathological muscle loss and weakness
US-2019125833-A1 · May 2, 2019 · US
Predicting response to cancer treatment with fgfr2 inhibitors
US-2017145103-A1 · May 25, 2017 · US
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US-2017145102-A1 · May 25, 2017 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Five Prime Therapeutics Inc | 14 |
| Bristol Myers Squibb Co | 3 |
| UCB Biopharma SRL | 3 |
| Glaxosmithkline Ip Dev Ltd | 2 |
| Johnson Timothy Scott | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K45/06 | 11 |
| A61P13/12 | 9 |
| A61P35/00 | 8 |
| A61P1/16 | 8 |
| A61K2039/507 | 8 |